Just A Product, Not A Pathway, FDA Says Of Omnitrope Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz' follow-on human growth hormone does not establish a precedent for follow-on proteins for biologics regulated under the Public Health Service Act.
You may also be interested in...
Advair Competition: Teva’s AirDuo Approved But Not Therapeutically Equivalent
US FDA approves Teva’s fluticasone/salmeterol fixed-dose combination product under the 505(b)(2) NDA route with an asthma indication but no labeling claim for chronic obstructive pulmonary disease.
Congress Will Look To “Hesitant” FDA To Regulate Biosimilars – Former HHS Deputy
Follow-on biologics, and their eventual road to approval, were weighty discussion topics on the opening day of the BIO CEO conference.
Congress Will Look To “Hesitant” FDA To Regulate Biosimilars – Former HHS Deputy
Follow-on biologics, and their eventual road to approval, were weighty discussion topics on the opening day of the BIO CEO conference.